PharmaVoice 12. Feb. 2026 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
PharmaVoice 29. Jan. 2026 Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
PharmaVoice 14. Jan. 2026 Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
PharmaVoice 24. Nov. 2025 Eli Lilly becomes first drugmaker to hit $1 trillion in market value #Eli Lilly #drugmaking peers